Stock market slides are rarely kind to development-stage biopharma companies. Did October's sell-off create any opportunities for investors?
News & Analysis: Galmed Pharmaceuticals
Analysts love this biotech, but should you?
The first treatments for this growing epidemic of liver disease will be huge blockbusters, and one of these biotechs could have what it takes.
Investors are piling into NASH stocks right now, but which ones are the best long-term buys?
Investors are cheering Galmed's experimental NASH drug, causing the biotech's shares to more than triple in value.